Sparsentan superior to irbesartan for reduction of proteinuria in patients with IgA nephropathy

1. Patients in sparsentan group reported a 50% reduction in proteinuria compared to 15% in the irbesartan group at week 36. 2. Complete remission of proteinuria was significantly higher in the sparsentan group. Evidence Rating Level: 1 (Excellent) Study Rundown: IgA nephropathy is the most common cause of primary glomerulonephritis worldwide. Although renin-angiotensin blockers (ARBs),

Related Keywords

,Rating Level ,Proteinuric Kidney Disease ,Between Dec ,Glomerulonephritis ,Iga Nephropathy ,Irbesartan ,Kidney ,Nephrology ,Nephropathy ,Prenal ,Sparsentan ,Chronic Disease ,Rheumatology ,